
TransMed7, LLC Announces First Revenue from Concorde Family of Devices
Portola Valley, CA, September 6, 2023 – TransMed7, LLC announced today the first sales of Concorde (Single Insertion / Multiple Collection (SIMC®)
Portola Valley, CA, September 6, 2023 – TransMed7, LLC announced today the first sales of Concorde (Single Insertion / Multiple Collection (SIMC®)
Portola Valley, CA, March 21, 2023 – TransMed7, LLC announced today the first clinical use of VacuPac®, a new self-contained external vacuum-assist
Portola Valley, CA, February 6, 2023 – TransMed7, LLC announced today that the “First in Human” series of clinical cases using commercial
Portola Valley, CA, August 16, 2022 – TransMed7, LLC announced today that the “First in Human” clinical case of the commercial production
Portola Valley, CA, August 8, 2022 – TransMed7, LLC announced today that the first clinical cases of the final commercial production version
PHOENIX, AZ, September 22, 2020 – TransMed7, LLC announced today that the first of the vacuum-assisted, Single Insertion – Multiple Collection (SIMC™)
Portola Valley, CA –TransMed7, LLC announced today that the United States Food and Drug Administration (FDA) has cleared its 510(k) application for the company to market TransMed7’s new Concorde USTM and Concorde STTM soft tissue biopsy devices.
TransMed7 is delighted to announce the ongoing production of prototype HeronTM devices for its newly announced Project Company, Heron MD, LLC. Annually
TransMed7’s Intellectual Property portfolio is built on a robust patent generation and protection strategy, developed and backed by deep expertise with our
We were delighted to present several prototype CardinalTM devices for the first time at this year’s ASBrS meeting. As expected, there was